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The DNA methylation modifying enzymes DNMT3A and TET2 are essential for proper 
differentiation of hematopoietic stem cells and are frequently found to be mutated in 
blood cancers. Although their functions in regulating DNA methylation have been 
characterized, a specific connection between methylation patterns and altered gene 
expression has not been established to explain the observed disease phenotype. We 
hypothesize that Dnmt3a and Tet2 mutant HSCs are dependent on other epigenetic 
regulators to corrupt normal hematopoietic pathways. If this is the case, inhibition of 
the chromatin modifiers on which driver mutations Dnmt3a and Tet2 depend could 
represent a novel therapeutic strategy for reducing the propagation of pre-leukemic 
HSC populations and preventing the onset of hematological malignancies. To test 
this hypothesis, we employed a CRISPR-Cas9 based negative selection screen on cells 
derived from DNMT3A-null and TET2-null HSCs, targeting 180 chromatin modifying 
genes. Results were obtained from three biological replicates, and those genes showing 
significant fold depletion over time in Dnmt3a-null or Tet2-null cells were selected 
for further investigation as potential therapeutic targets. Specifically, Esco1, Brd2 
and Zmynd8 are being considered for future directions. Ultimately, we conclude that 
our negative selection CRISPR screen is optimized to detect those genes potentially 
showing an epigenetic dependence with DNMT3A and TET2 in hematopoiesis, and that 
functional studies in vivo are needed to validate and further define our in vitro findings.
